558 related articles for article (PubMed ID: 24325405)
41. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy.
Suppiah V; Moldovan M; Ahlenstiel G; Berg T; Weltman M; Abate ML; Bassendine M; Spengler U; Dore GJ; Powell E; Riordan S; Sheridan D; Smedile A; Fragomeli V; Müller T; Bahlo M; Stewart GJ; Booth DR; George J
Nat Genet; 2009 Oct; 41(10):1100-4. PubMed ID: 19749758
[TBL] [Abstract][Full Text] [Related]
42. IL28B polymorphism and cytomegalovirus predict response to treatment in Egyptian HCV type 4 patients.
El Awady MK; Bader El Din NG; Tabll A; El Hosary Y; Abdel Aziz AO; El Khayat H; Salama M; Abdelhafez TH
World J Gastroenterol; 2013 Jan; 19(2):290-8. PubMed ID: 23345953
[TBL] [Abstract][Full Text] [Related]
43. Telaprevir is effective given every 12 h at 750 mg with pegylated interferon-α2b and ribavirin to Japanese patients with HCV-1b IL28B rs8099917 TT.
Kawakami Y; Suzuki F; Karino Y; Toyota J; Kumada H; Chayama K
Antivir Ther; 2014; 19(3):277-85. PubMed ID: 24192751
[TBL] [Abstract][Full Text] [Related]
44. Estimation of two real-time RT-PCR assays for quantitation of hepatitis C virus RNA during PEG-IFN plus ribavirin therapy by HCV genotypes and IL28B genotype.
Miyagi Y; Nomura H; Yamashita N; Tanimoto H; Ito K; Masaki N; Mizokami M; Shibuya T
J Infect Chemother; 2013 Feb; 19(1):63-9. PubMed ID: 22821355
[TBL] [Abstract][Full Text] [Related]
45. Impact of the peginterferon-α 2a and ribavirin plasma levels on viral kinetics and sustained virological response in genotype 1 HCV/HIV-co-infected patients with the unfavourable non-CC IL28B genotypes.
Torres-Cornejo A; Ruiz-Valderas R; Jimenez-Jimenez L; Abad-Molina C; Gutierrez-Valencia A; Viciana P; Lopez-Cortes LF
J Viral Hepat; 2014 Mar; 21(3):178-88. PubMed ID: 24438679
[TBL] [Abstract][Full Text] [Related]
46. The impact of IL28B genotype on the gene expression profile of patients with chronic hepatitis C treated with pegylated interferon alpha and ribavirin.
Younossi ZM; Birerdinc A; Estep M; Stepanova M; Afendy A; Baranova A
J Transl Med; 2012 Feb; 10():25. PubMed ID: 22313623
[TBL] [Abstract][Full Text] [Related]
47. A single nucleotide polymorphism, rs129679860, in the IL28B locus is associated with the viral kinetics and a sustained virological response in a chronic, monoinfected hepatitis C virus genotype-1 Brazilian population treated with pegylated interferon-ribavirin.
Ramos JA; Ramos AL; Hoffmann L; Perez Rde M; Coelho HS; Urményi TP; Silva R; Rondinelli E; Villela-Nogueira CA
Mem Inst Oswaldo Cruz; 2012 Nov; 107(7):888-92. PubMed ID: 23147144
[TBL] [Abstract][Full Text] [Related]
48. What's new in HCV genotype 2 treatment.
Mangia A; Mottola L
Liver Int; 2012 Feb; 32 Suppl 1():135-40. PubMed ID: 22212584
[TBL] [Abstract][Full Text] [Related]
49. Patients younger than forty years old with hepatitis C virus genotype-1 chronic infection had treatment responses similar to genotype-2 infection and not related to interleukin-28B polymorphism.
Lin CY; Sheen IS; Jeng WJ; Huang CW; Huang CH; Chen JY
Ann Hepatol; 2013; 12(1):62-9. PubMed ID: 23293195
[TBL] [Abstract][Full Text] [Related]
50. Association study of IL28B: rs12979860 and rs8099917 polymorphisms with SVR in patients infected with chronic HCV genotype 1 to PEG-INF/RBV therapy using systematic meta-analysis.
Luo Y; Jin C; Ling Z; Mou X; Zhang Q; Xiang C
Gene; 2013 Jan; 513(2):292-6. PubMed ID: 23142377
[TBL] [Abstract][Full Text] [Related]
51. IL28B genomic-based treatment paradigms for patients with chronic hepatitis C infection: the future of personalized HCV therapies.
Clark PJ; Thompson AJ; McHutchison JG
Am J Gastroenterol; 2011 Jan; 106(1):38-45. PubMed ID: 20924369
[TBL] [Abstract][Full Text] [Related]
52. IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection.
Moghaddam A; Melum E; Reinton N; Ring-Larsen H; Verbaan H; Bjøro K; Dalgard O
Hepatology; 2011 Mar; 53(3):746-54. PubMed ID: 21374656
[TBL] [Abstract][Full Text] [Related]
53. [PROGNOSTIC VALUE OF THE COMBINATION OF BLOOD GROUP SPECIFICITY AND INTERLEUKIN 28B GENE POLYMORPHISM FOR ESTIMATION OF EFFICIENCY OF THERAPY WITH THE USE OF PEGYLATED INTERFERON α-2 AND RIBAVARIN IN PATIENTS WITH CHRONIC GENOTYPE 1 HEPATITIS C].
Ogurtsov PP; Kukhareva EI
Klin Med (Mosk); 2016; 94(3):224-30. PubMed ID: 27522730
[TBL] [Abstract][Full Text] [Related]
54. Interferon-λ3 polymorphisms in pegylated-interferon-α plus ribavirin therapy for genotype-2 chronic hepatitis C.
Ishiguro H; Abe H; Seki N; Sugita T; Aida Y; Itagaki M; Sutoh S; Shimada N; Furihata T; Tsubota A; Aizawa Y
World J Gastroenterol; 2015 Apr; 21(13):3904-11. PubMed ID: 25852275
[TBL] [Abstract][Full Text] [Related]
55. Baseline factors associated with treatment response in patients infected with hepatitis C virus 1b by stratification of IL28B polymorphisms.
Ling Q; Chen J; Zhou H; Zhong J; Chen Y; Ye Q; Zhuo Y; Min N; Shang B
Arch Virol; 2015 Apr; 160(4):1105-12. PubMed ID: 25687192
[TBL] [Abstract][Full Text] [Related]
56. Meta-analysis: IL28B polymorphisms predict sustained viral response in HCV patients treated with pegylated interferon-α and ribavirin.
Chen Y; Xu HX; Wang LJ; Liu XX; Mahato RI; Zhao YR
Aliment Pharmacol Ther; 2012 Jul; 36(2):91-103. PubMed ID: 22591106
[TBL] [Abstract][Full Text] [Related]
57. Hepatitis C pharmacogenetics: state of the art in 2010.
Afdhal NH; McHutchison JG; Zeuzem S; Mangia A; Pawlotsky JM; Murray JS; Shianna KV; Tanaka Y; Thomas DL; Booth DR; Goldstein DB;
Hepatology; 2011 Jan; 53(1):336-45. PubMed ID: 21254181
[TBL] [Abstract][Full Text] [Related]
58. Valuable antiviral therapeutic options for the treatment of chronic hepatitis C patients with thrombocytopenia.
Ogawa E; Furusyo N; Murata M; Ikezaki H; Ihara T; Hayashi T; Toyoda K; Okada K; Kainuma M; Kajiwara E; Takahashi K; Satoh T; Hayashi J
J Viral Hepat; 2013 Dec; 20(12):838-46. PubMed ID: 24304453
[TBL] [Abstract][Full Text] [Related]
59. Association between IL28B polymorphisms and first-phase viral load decrease in chronic hepatitis C virus-infected patients treated with peginterferon alfa-2b/ribavirin.
Arends JE; Fransen JH; Hoepelman AI; van Baarle D
Int J Antimicrob Agents; 2011 Dec; 38(6):538-9. PubMed ID: 21974859
[TBL] [Abstract][Full Text] [Related]
60. Host genetics.
Macías J; Vispo E; Pineda JA; Soriano V
Curr Opin HIV AIDS; 2011 Nov; 6(6):491-500. PubMed ID: 21918436
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
